Initially, therapeutic approaches for improving cholinergic neurotransmission have focused on the use of AChE inhibitors, but successively several works demonstrated the relevance of both enzymes in the physio-pathology of AD, establishing the therapeutic importance to inhibit both AChE and BChE [13,14,15]. This evidence concerns the gene ACHE and Alzheimer disease.